<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02064777</url>
  </required_header>
  <id_info>
    <org_study_id>2012MAR19</org_study_id>
    <nct_id>NCT02064777</nct_id>
  </id_info>
  <brief_title>Prospective Tacrolimus Pharmacokinetics Study in Pediatric Living Donor Liver Transplantation</brief_title>
  <official_title>Tacrolimus Disposition in Pediatric Transplantation: Influence of Age, Genetic Polymorphisms, Intestinal and Hepatic Relative Contribution on Pharmacokinetics, in Relationship With Clinical Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our first aim is thus to investigate, retrospectively first and then prospectively, in de
      novo pediatric (living donor) liver recipients, the tacrolimus in vivo and in vitro
      metabolism and its variability with focus on pharmacokinetics, pharmacodynamics, and
      pharmacogenomics and its evolution according to the age and transplant delay. Our second aim
      is then to find better tacrolimus exposure markers for therapeutic drug monitoring (TDM) such
      as Area Under the time-concentration Curve (AUC) or intralymphocytic (PBMCs) tacrolimus
      concentration and a way to model and predict it without invasive tests in pediatric patients.

      The final objective should be then to implement these findings in a more individualized and
      comprehensive immunosuppression protocol and monitoring in order to maintain adequate and
      well-balanced immunosuppression (preventing graft rejection while avoiding acute and
      long-term side effects). This is particularly important for a pediatric population exposed
      throughout their life to immunosuppressants.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Time Concentration curve</measure>
    <time_frame>day 2-day 4; day 10-day 1; &gt; day 21</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intralymphocytic tacrolimus concentration</measure>
    <time_frame>Day 3</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pediatric Liver Transplantation</condition>
  <arm_group>
    <arm_group_label>Tacrolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <arm_group_label>Tacrolimus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children aged 0 to 18 years

          -  First Liver transplantation

          -  Children eligible to receive tacrolimus post transplantation

          -  Consent from parents

        Exclusion Criteria:

          -  Multiorgan transplantation

          -  Retransplantation

          -  ABO incompatible donors (unless if recipients is&lt;1 year and anti-AB antibodies are
             &lt;1/32)

          -  Multi organ failure

          -  Need for additionnal therapy except for methylprednisolone to treat rejection

          -  Intravenous tacrolimus

          -  First tacrolimus administration postponed after day 3
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Vanessa Guy-Viterbo, MD</last_name>
    <phone>003227649472</phone>
    <email>vanessa.guy@uclouvain.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Raymond Reding, MD-PhD</last_name>
    <phone>003227641401</phone>
    <email>raymond.reding@uclouvain.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cliniques Universitaires St-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Raymond Reding, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vanessa Guy-Viterbo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2014</study_first_submitted>
  <study_first_submitted_qc>February 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2014</study_first_posted>
  <last_update_submitted>February 14, 2014</last_update_submitted>
  <last_update_submitted_qc>February 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

